FIGURE 1 from Molecular Landscape and Clinical Implication of CCNE1-amplified Esophagogastric Cancer

Incidence of CCNE1 amplification in EGC by real-world analysis. NGS, including targeted and WES, was performed on 7,083 patients including 751 patients with ESCC, 2,276 patients with EA, 1,449 patients with EJC, and 2,607 patients with gastric adenocarcinoma (A). CN distribution of CCNE1 is reported by total numbers for EAC, ESCC, gastric adenocarcinoma, and EJC. CCNE1 amplification is defined as a CN ≥ 6 which is denoted by the black line. Percent CCNE1 amplification across cancer types (B). CCNE1 amplification by site, either primary tumor or metastasis, is shown for EAC, gastric adenocarcinoma, and EJC (C).